Product image of Mannitol Biosedra (Mannitol) supplied by GNH India

Mannitol Biosedra

Active Ingredient:
Mannitol
Origin:
EU

Mannitol Biosedra (Mannitol)

Mannitol, the active ingredient in Mannitol Biosedra, is an osmotic diuretic presented as a solution for injection for intravenous use. It reduces elevated intracranial pressure, assists in managing cerebral edema, and promotes diuresis in acute renal failure or toxic ingestions.

GNH India supplies Mannitol Biosedra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Products are shipped with full documentation to meet local health authority requirements.

Manufacturer / TM Owner

Fresenius Kabi France S.A.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mannitol is used in clinical situations that require osmotic reduction of fluid compartments, particularly in the central nervous system and renal contexts.
  • Elevated intracranial pressure: lowers pressure and helps resolve cerebral edema.
  • Acute renal failure: enhances urine output to assist fluid balance.
  • Toxic ingestions (e.g., certain drug overdoses): increases renal clearance of harmful substances.

How It Works

  • Mannitol acts as an osmotically active agent that raises plasma osmolarity when administered intravenously. The increased extracellular osmolarity draws water from intracellular and interstitial spaces into the vascular compartment, producing an osmotic diuresis. In the brain, this shift reduces cerebral volume and intracranial pressure, while in the kidneys it promotes filtration and excretion of solutes and toxins, and facilitates overall fluid homeostasis.

Side Effects

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Headache: mild to moderate pain often related to rapid osmotic shifts.
  • Nausea or vomiting: gastrointestinal discomfort after infusion.
  • Transient hypotension: temporary drop in blood pressure during or shortly after administration.

Serious or Rare Side Effects

  • Acute renal failure: worsening kidney function in susceptible patients.
  • Pulmonary edema: fluid accumulation in lungs due to rapid volume shifts.
  • Severe electrolyte disturbances: hypernatremia or severe hypokalemia requiring medical intervention.

Precautions & Warnings

When using Mannitol Biosedra, clinicians should observe several safety measures.

  • Assess renal function: evaluate creatinine clearance before initiating therapy.
  • Monitor fluid balance: track input, output, and weight to avoid overload.
  • Check electrolytes: regularly measure serum sodium, potassium, and osmolality.
  • Use caution in patients with heart failure: risk of volume overload.
  • Avoid rapid infusion rates: administer over recommended time to reduce neurologic symptoms.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mannitol can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid)

  • Loop diuretics (e.g., furosemide): additive diuretic effect may cause severe dehydration and electrolyte loss.
  • Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increased risk of renal impairment when combined with Mannitol.

Moderate Interactions (Monitor Closely)

  • Antihypertensives (e.g., ACE inhibitors, ARBs): may potentiate hypotensive response.
  • Insulin or oral hypoglycemics: osmotic shifts can affect glucose control, requiring monitoring.
  • Lithium: altered renal clearance may increase lithium levels.

Frequently Asked Questions

Mannitol Biosedra is an intravenous osmotic diuretic indicated for lowering elevated intracranial pressure, managing cerebral edema, promoting diuresis in acute renal failure, and facilitating renal excretion of certain toxins in cases of toxic ingestion.

Mannitol increases plasma osmolarity after intravenous administration, drawing water from intracellular and interstitial compartments into the vascular space. This osmotic shift creates a diuretic effect, reduces cerebral volume, and lowers intracranial pressure while enhancing renal filtration and toxin clearance.

The specific dose and infusion rate of Mannitol Biosedra are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. No standardized dosing regimen is provided here.

Safety data for Mannitol in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order, submit an enquiry on the Mannitol Biosedra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mannitol is the most widely used osmotic diuretic for rapid reduction of intracranial pressure and promotion of diuresis. Compared with agents such as hypertonic saline, Mannitol provides a predictable osmotic effect and is readily eliminated by the kidneys, but it requires careful monitoring of renal function and electrolytes.

Mannitol Biosedra should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability.

Mannitol Biosedra is administered intravenously as a sterile solution for injection. It is typically infused over a controlled period as directed by the prescriber, using appropriate infusion sets and monitoring equipment to observe patient response.

Serious risks include acute renal failure, pulmonary edema from rapid fluid shifts, and severe electrolyte disturbances such as hypernatremia or profound hypokalemia. Prompt recognition and management of these events are essential to prevent morbidity.

Mannitol is contraindicated in patients with established anuria, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or known hypersensitivity to Mannitol. Clinicians should evaluate each patient’s clinical status before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.